A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of the Selective D3 Antagonist, GSK598809, Added to CBT (Cognitive Behavioral Therapy) and NRT (Nicotine Replacement Therapy) for Smoking Cessation and Prevention of Very Early Relapse to Smoking

Trial Profile

A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of the Selective D3 Antagonist, GSK598809, Added to CBT (Cognitive Behavioral Therapy) and NRT (Nicotine Replacement Therapy) for Smoking Cessation and Prevention of Very Early Relapse to Smoking

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs GSK 598809 (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top